Cargando…
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial
IMPORTANCE: Aurora A kinase (AURKA) activation, related in part to AURKA amplification and variants, is associated with downregulation of estrogen receptor (ER) α expression, endocrine resistance, and implicated in cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) resistance. Alisertib, a selective A...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999287/ https://www.ncbi.nlm.nih.gov/pubmed/36892847 http://dx.doi.org/10.1001/jamaoncol.2022.7949 |
_version_ | 1784903631784378368 |
---|---|
author | Haddad, Tufia C. Suman, Vera J. D’Assoro, Antonino B. Carter, Jodi M. Giridhar, Karthik V. McMenomy, Brendan P. Santo, Katelyn Mayer, Erica L. Karuturi, Meghan S. Morikawa, Aki Marcom, P. Kelly Isaacs, Claudine J. Oh, Sun Young Clark, Amy S. Mayer, Ingrid A. Keyomarsi, Khandan Hobday, Timothy J. Peethambaram, Prema P. O’Sullivan, Ciara C. Leon-Ferre, Roberto A. Liu, Minetta C. Ingle, James N. Goetz, Matthew P. |
author_facet | Haddad, Tufia C. Suman, Vera J. D’Assoro, Antonino B. Carter, Jodi M. Giridhar, Karthik V. McMenomy, Brendan P. Santo, Katelyn Mayer, Erica L. Karuturi, Meghan S. Morikawa, Aki Marcom, P. Kelly Isaacs, Claudine J. Oh, Sun Young Clark, Amy S. Mayer, Ingrid A. Keyomarsi, Khandan Hobday, Timothy J. Peethambaram, Prema P. O’Sullivan, Ciara C. Leon-Ferre, Roberto A. Liu, Minetta C. Ingle, James N. Goetz, Matthew P. |
author_sort | Haddad, Tufia C. |
collection | PubMed |
description | IMPORTANCE: Aurora A kinase (AURKA) activation, related in part to AURKA amplification and variants, is associated with downregulation of estrogen receptor (ER) α expression, endocrine resistance, and implicated in cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) resistance. Alisertib, a selective AURKA inhibitor, upregulates ERα and restores endocrine sensitivity in preclinical metastatic breast cancer (MBC) models. The safety and preliminary efficacy of alisertib was demonstrated in early-phase trials; however, its activity in CDK 4/6i–resistant MBC is unknown. OBJECTIVE: To assess the effect of adding fulvestrant to alisertib on objective tumor response rates (ORRs) in endocrine-resistant MBC. DESIGN, SETTING, AND PARTICIPANTS: This phase 2 randomized clinical trial was conducted through the Translational Breast Cancer Research Consortium, which enrolled participants from July 2017 to November 2019. Postmenopausal women with endocrine-resistant, ERBB2 (formerly HER2)–negative MBC who were previously treated with fulvestrant were eligible. Stratification factors included prior treatment with CDK 4/6i, baseline metastatic tumor ERα level measurement (<10%, ≥10%), and primary or secondary endocrine resistance. Among 114 preregistered patients, 96 (84.2%) registered and 91 (79.8%) were evaluable for the primary end point. Data analysis began after January 10, 2022. INTERVENTIONS: Alisertib, 50 mg, oral, daily on days 1 to 3, 8 to 10, and 15 to 17 of a 28-day cycle (arm 1) or alisertib same dose/schedule with standard-dose fulvestrant (arm 2). MAIN OUTCOMES AND MEASURES: Improvement in ORR in arm 2 of at least 20% greater than arm 1 when the expected ORR for arm 1 was 20%. RESULTS: All 91 evaluable patients (mean [SD] age, 58.5 [11.3] years; 1 American Indian/Alaskan Native [1.1%], 2 Asian [2.2%], 6 Black/African American [6.6%], 5 Hispanic [5.5%], and 79 [86.8%] White individuals; arm 1, 46 [50.5%]; arm 2, 45 [49.5%]) had received prior treatment with CDK 4/6i. The ORR was 19.6%; (90% CI, 10.6%-31.7%) for arm 1 and 20.0% (90% CI, 10.9%-32.3%) for arm 2. In arm 1, the 24-week clinical benefit rate and median progression-free survival time were 41.3% (90% CI, 29.0%-54.5%) and 5.6 months (95% CI, 3.9-10.0), respectively, and in arm 2 they were 28.9% (90% CI, 18.0%-42.0%) and 5.4 months (95% CI, 3.9-7.8), respectively. The most common grade 3 or higher adverse events attributed to alisertib were neutropenia (41.8%) and anemia (13.2%). Reasons for discontinuing treatment were disease progression (arm 1, 38 [82.6%]; arm 2, 31 [68.9%]) and toxic effects or refusal (arm 1, 5 [10.9%]; arm 2, 12 [26.7%]). CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that adding fulvestrant to treatment with alisertib did not increase ORR or PFS; however, promising clinical activity was observed with alisertib monotherapy among patients with endocrine-resistant and CDK 4/6i–resistant MBC. The overall safety profile was tolerable. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02860000 |
format | Online Article Text |
id | pubmed-9999287 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-99992872023-03-11 Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial Haddad, Tufia C. Suman, Vera J. D’Assoro, Antonino B. Carter, Jodi M. Giridhar, Karthik V. McMenomy, Brendan P. Santo, Katelyn Mayer, Erica L. Karuturi, Meghan S. Morikawa, Aki Marcom, P. Kelly Isaacs, Claudine J. Oh, Sun Young Clark, Amy S. Mayer, Ingrid A. Keyomarsi, Khandan Hobday, Timothy J. Peethambaram, Prema P. O’Sullivan, Ciara C. Leon-Ferre, Roberto A. Liu, Minetta C. Ingle, James N. Goetz, Matthew P. JAMA Oncol Original Investigation IMPORTANCE: Aurora A kinase (AURKA) activation, related in part to AURKA amplification and variants, is associated with downregulation of estrogen receptor (ER) α expression, endocrine resistance, and implicated in cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) resistance. Alisertib, a selective AURKA inhibitor, upregulates ERα and restores endocrine sensitivity in preclinical metastatic breast cancer (MBC) models. The safety and preliminary efficacy of alisertib was demonstrated in early-phase trials; however, its activity in CDK 4/6i–resistant MBC is unknown. OBJECTIVE: To assess the effect of adding fulvestrant to alisertib on objective tumor response rates (ORRs) in endocrine-resistant MBC. DESIGN, SETTING, AND PARTICIPANTS: This phase 2 randomized clinical trial was conducted through the Translational Breast Cancer Research Consortium, which enrolled participants from July 2017 to November 2019. Postmenopausal women with endocrine-resistant, ERBB2 (formerly HER2)–negative MBC who were previously treated with fulvestrant were eligible. Stratification factors included prior treatment with CDK 4/6i, baseline metastatic tumor ERα level measurement (<10%, ≥10%), and primary or secondary endocrine resistance. Among 114 preregistered patients, 96 (84.2%) registered and 91 (79.8%) were evaluable for the primary end point. Data analysis began after January 10, 2022. INTERVENTIONS: Alisertib, 50 mg, oral, daily on days 1 to 3, 8 to 10, and 15 to 17 of a 28-day cycle (arm 1) or alisertib same dose/schedule with standard-dose fulvestrant (arm 2). MAIN OUTCOMES AND MEASURES: Improvement in ORR in arm 2 of at least 20% greater than arm 1 when the expected ORR for arm 1 was 20%. RESULTS: All 91 evaluable patients (mean [SD] age, 58.5 [11.3] years; 1 American Indian/Alaskan Native [1.1%], 2 Asian [2.2%], 6 Black/African American [6.6%], 5 Hispanic [5.5%], and 79 [86.8%] White individuals; arm 1, 46 [50.5%]; arm 2, 45 [49.5%]) had received prior treatment with CDK 4/6i. The ORR was 19.6%; (90% CI, 10.6%-31.7%) for arm 1 and 20.0% (90% CI, 10.9%-32.3%) for arm 2. In arm 1, the 24-week clinical benefit rate and median progression-free survival time were 41.3% (90% CI, 29.0%-54.5%) and 5.6 months (95% CI, 3.9-10.0), respectively, and in arm 2 they were 28.9% (90% CI, 18.0%-42.0%) and 5.4 months (95% CI, 3.9-7.8), respectively. The most common grade 3 or higher adverse events attributed to alisertib were neutropenia (41.8%) and anemia (13.2%). Reasons for discontinuing treatment were disease progression (arm 1, 38 [82.6%]; arm 2, 31 [68.9%]) and toxic effects or refusal (arm 1, 5 [10.9%]; arm 2, 12 [26.7%]). CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that adding fulvestrant to treatment with alisertib did not increase ORR or PFS; however, promising clinical activity was observed with alisertib monotherapy among patients with endocrine-resistant and CDK 4/6i–resistant MBC. The overall safety profile was tolerable. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02860000 American Medical Association 2023-03-09 2023-06 /pmc/articles/PMC9999287/ /pubmed/36892847 http://dx.doi.org/10.1001/jamaoncol.2022.7949 Text en Copyright 2023 Haddad TC et al. JAMA Oncology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License. |
spellingShingle | Original Investigation Haddad, Tufia C. Suman, Vera J. D’Assoro, Antonino B. Carter, Jodi M. Giridhar, Karthik V. McMenomy, Brendan P. Santo, Katelyn Mayer, Erica L. Karuturi, Meghan S. Morikawa, Aki Marcom, P. Kelly Isaacs, Claudine J. Oh, Sun Young Clark, Amy S. Mayer, Ingrid A. Keyomarsi, Khandan Hobday, Timothy J. Peethambaram, Prema P. O’Sullivan, Ciara C. Leon-Ferre, Roberto A. Liu, Minetta C. Ingle, James N. Goetz, Matthew P. Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial |
title | Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial |
title_full | Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial |
title_fullStr | Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial |
title_full_unstemmed | Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial |
title_short | Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial |
title_sort | evaluation of alisertib alone or combined with fulvestrant in patients with endocrine-resistant advanced breast cancer: the phase 2 tbcrc041 randomized clinical trial |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999287/ https://www.ncbi.nlm.nih.gov/pubmed/36892847 http://dx.doi.org/10.1001/jamaoncol.2022.7949 |
work_keys_str_mv | AT haddadtufiac evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT sumanveraj evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT dassoroantoninob evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT carterjodim evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT giridharkarthikv evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT mcmenomybrendanp evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT santokatelyn evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT mayererical evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT karuturimeghans evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT morikawaaki evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT marcompkelly evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT isaacsclaudinej evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT ohsunyoung evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT clarkamys evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT mayeringrida evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT keyomarsikhandan evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT hobdaytimothyj evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT peethambarampremap evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT osullivanciarac evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT leonferrerobertoa evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT liuminettac evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT inglejamesn evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial AT goetzmatthewp evaluationofalisertibaloneorcombinedwithfulvestrantinpatientswithendocrineresistantadvancedbreastcancerthephase2tbcrc041randomizedclinicaltrial |